Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) major shareholder Endurance (Cayman) Ltd Svf sold 78,930 shares of the company's stock in a transaction on Monday, January 30th. The shares were sold at an average price of $29.46, for a total value of $2,325,277.80. Following the completion of the transaction, the insider now owns 19,267,582 shares of the company's stock, valued at $567,622,965.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Endurance (Cayman) Ltd Svf also recently made the following trade(s):
Get
Vir Biotechnology alerts:
- On Monday, January 23rd, Endurance (Cayman) Ltd Svf sold 36,512 shares of Vir Biotechnology stock. The shares were sold at an average price of $28.34, for a total value of $1,034,750.08.
- On Thursday, January 19th, Endurance (Cayman) Ltd Svf sold 69,839 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.56, for a total value of $1,854,923.84.
- On Tuesday, January 17th, Endurance (Cayman) Ltd Svf sold 88,372 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.24, for a total value of $2,318,881.28.
- On Friday, January 13th, Endurance (Cayman) Ltd Svf sold 94,199 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.54, for a total value of $2,500,041.46.
- On Wednesday, January 11th, Endurance (Cayman) Ltd Svf sold 79,065 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.24, for a total value of $2,074,665.60.
- On Monday, January 9th, Endurance (Cayman) Ltd Svf sold 34,801 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.85, for a total value of $899,605.85.
- On Friday, January 6th, Endurance (Cayman) Ltd Svf sold 66,179 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.13, for a total value of $1,729,257.27.
- On Tuesday, January 3rd, Endurance (Cayman) Ltd Svf sold 8,177 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.58, for a total value of $209,167.66.
- On Tuesday, December 27th, Endurance (Cayman) Ltd Svf sold 6,850 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.59, for a total value of $175,291.50.
- On Thursday, December 22nd, Endurance (Cayman) Ltd Svf sold 95,144 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.07, for a total value of $2,480,404.08.
Vir Biotechnology Stock Performance
NASDAQ:VIR opened at $29.91 on Friday. Vir Biotechnology, Inc. has a one year low of $18.05 and a one year high of $34.97. The business's 50-day simple moving average is $26.78 and its 200 day simple moving average is $25.14. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of 3.52 and a beta of 0.19.
Vir Biotechnology (NASDAQ:VIR – Get Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported $1.30 EPS for the quarter, topping the consensus estimate of $0.01 by $1.29. The business had revenue of $374.56 million during the quarter, compared to analyst estimates of $153.79 million. On average, equities research analysts predict that Vir Biotechnology, Inc. will post 4.6 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the business. BlackRock Inc. lifted its stake in shares of Vir Biotechnology by 8.3% in the third quarter. BlackRock Inc. now owns 13,873,726 shares of the company's stock worth $267,486,000 after acquiring an additional 1,062,036 shares in the last quarter. Vanguard Group Inc. raised its stake in Vir Biotechnology by 21.1% during the third quarter. Vanguard Group Inc. now owns 9,928,416 shares of the company's stock valued at $191,420,000 after buying an additional 1,731,172 shares in the last quarter. Temasek Holdings Private Ltd raised its stake in Vir Biotechnology by 7.8% during the third quarter. Temasek Holdings Private Ltd now owns 6,036,821 shares of the company's stock valued at $116,390,000 after buying an additional 434,268 shares in the last quarter. State Street Corp raised its stake in Vir Biotechnology by 5.6% during the third quarter. State Street Corp now owns 5,830,417 shares of the company's stock valued at $112,410,000 after buying an additional 311,279 shares in the last quarter. Finally, Baillie Gifford & Co. raised its stake in Vir Biotechnology by 1.2% during the third quarter. Baillie Gifford & Co. now owns 3,978,657 shares of the company's stock valued at $76,709,000 after buying an additional 47,805 shares in the last quarter. Institutional investors and hedge funds own 74.97% of the company's stock.
Analysts Set New Price Targets
VIR has been the subject of several analyst reports. Morgan Stanley raised Vir Biotechnology from an "underweight" rating to an "equal weight" rating and upped their target price for the stock from $18.00 to $30.00 in a research report on Friday, January 27th. SVB Leerink decreased their target price on Vir Biotechnology from $45.00 to $43.00 and set an "outperform" rating for the company in a research report on Friday, January 27th. TheStreet raised Vir Biotechnology from a "d" rating to a "c-" rating in a research report on Monday, October 10th. Finally, Needham & Company LLC decreased their target price on Vir Biotechnology from $35.00 to $32.00 and set a "buy" rating for the company in a research report on Friday, November 4th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $54.17.
Vir Biotechnology Company Profile
(Get Rating)
Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
Featured Stories
- Get a free copy of the StockNews.com research report on Vir Biotechnology (VIR)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
